A modified perfusion protocol for pulmonary endarterectomy in a patient with a hematologic malignancy treated with a tyrosine kinase inhibitor.
Renard G HaumannDedré BuysEline HoflandHans Wa RomijnSuzanne K KammingaJurjan AmanEsther J NossentPetr SymerskyPublished in: Perfusion (2021)
Tyrosine kinase inhibitors (TKI) are known to be highly effective in the treatment of various cancers with kinase-domain mutations such as chronic myelogenous leukemia. However, they have important side effects such as increased vascular permeability and pulmonary hypertension. In patients undergoing pulmonary endarterectomy with deep hypothermic circulatory arrest, these side effects may exacerbate postoperative complications such as reperfusion edema and persistent pulmonary hypertension. We report on a simple modification of the perfusion strategy to increase intravascular oncotic pressure by retrograde autologous priming and the addition of packed cells and albumin in a patient treated with a TKI.
Keyphrases
- pulmonary hypertension
- pulmonary artery
- tyrosine kinase
- pulmonary arterial hypertension
- patients undergoing
- case report
- chronic myeloid leukemia
- bone marrow
- induced apoptosis
- advanced non small cell lung cancer
- coronary artery bypass grafting
- randomized controlled trial
- contrast enhanced
- acute myeloid leukemia
- coronary artery
- cell cycle arrest
- acute myocardial infarction
- heart failure
- newly diagnosed
- cell death
- acute ischemic stroke
- cell therapy
- magnetic resonance imaging
- stem cells
- left ventricular
- epidermal growth factor receptor
- percutaneous coronary intervention
- computed tomography
- oxidative stress
- signaling pathway
- protein kinase
- coronary artery disease
- cerebral ischemia
- platelet rich plasma
- mesenchymal stem cells
- pi k akt